| 臺大學術典藏 |
2020-05-26T09:26:18Z |
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer
|
Yun M.R;Choi H.M;Lee Y.W;Joo H.S;Park C.W;Choi J.W;Kim D.H;Kang H.N;Pyo K.-H;Shin E.J;Shim H.S;Soo R.A;Chih-Hsin Yang;Lee S.S;Chang H;Kim M.H;Hong M.H;Kim H.R;Cho B.C.; Yun M.R; Choi H.M; Lee Y.W; Joo H.S; Park C.W; Choi J.W; Kim D.H; Kang H.N; Pyo K.-H; Shin E.J; Shim H.S; Soo R.A; CHIH-HSIN YANG; Lee S.S; Chang H; Kim M.H; Hong M.H; Kim H.R; Cho B.C. |
| 臺大學術典藏 |
2020-05-25T07:35:14Z |
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
|
Yang J.C.-H.; Yang Z; Overend P; Kao S; Goldman J.W; Su W.-C; Natale R; Rabbie S; Harrop B; John T; Kim H.R; Chia-Chi Lin; Kim T.M; Ahn J.-S; Lee J.S; Kim S.-W; Cho B.C; Kim D.-W; Ahn M.-J |
| 臺大學術典藏 |
2020-05-25T07:35:09Z |
Combination of the S49076 with gefitinib in NSCLC patients progressing on EGFR-TKI and harboring MET/AXL dysregulation
|
Viteri S; Chang G.-C; Chiari R; Cho B.C; Ciardiello F; Curigliano G; Hida T; Lee D.H; Lim W.T.D; Chia-Chi Lin; Martinez A; Murakami H; Natsume I; Nishio M; Paz-Ares L; Soo R.A; Cattan V; Gandossi E; Heck H; Park K. |
| 臺大學術典藏 |
2020-05-25T07:35:06Z |
Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2
|
Barlesi F; Drilon A; De Braud F; Cho B.C; Ahn M.J; Siena S; Krebs M.G; Chia-Chi Lin; John T; Tan D.S.W; Seto T; Dziadziuszko R; Arkenau H.-T; Rolfo C; Wolf J; Ye C; Riehl T; Eng S; Doebele R.C. |
| 臺大學術典藏 |
2020-05-25T07:35:02Z |
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1�V2 trials
|
Rolfo C; de Braud F; Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs M.G; Shaw A.T; Doebele R.C.;Wilson T.R;Eng S;Johnson A;Cui N;Simmons B;Chow-Maneval E;Riehl T;Prenen H;Tan D.S.W;Chia-Chi Lin;Murakami H;Otterson G.A;Chung C.H;Chae Y.K;Li Y.-C;Ohe Y;Kim S.-W;Arkenau H.-T;Karapetis C.S;Goto K;John T;Chiu C.-H;Patel M.R;Cho B.C;Seto T;Wolf J;Ahn M.-J;Rolfo C;de Braud F;Shaw A.T;Krebs M.G;Barlesi F;Dziadziuszko R;Siena S;Drilon A; Ahn M.-J; Wolf J; Seto T; Cho B.C; Patel M.R; Chiu C.-H; John T; Goto K; Karapetis C.S; Arkenau H.-T; Kim S.-W; Ohe Y; Li Y.-C; Chae Y.K; Chung C.H; Otterson G.A; Murakami H; Chia-Chi Lin; Tan D.S.W; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson T.R; Doebele R.C. |
| 臺大學術典藏 |
2020-05-25T07:35:02Z |
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1�V2 trials
|
Rolfo C; de Braud F; Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs M.G; Shaw A.T; Doebele R.C.;Wilson T.R;Eng S;Johnson A;Cui N;Simmons B;Chow-Maneval E;Riehl T;Prenen H;Tan D.S.W;Chia-Chi Lin;Murakami H;Otterson G.A;Chung C.H;Chae Y.K;Li Y.-C;Ohe Y;Kim S.-W;Arkenau H.-T;Karapetis C.S;Goto K;John T;Chiu C.-H;Patel M.R;Cho B.C;Seto T;Wolf J;Ahn M.-J;Rolfo C;de Braud F;Shaw A.T;Krebs M.G;Barlesi F;Dziadziuszko R;Siena S;Drilon A; Ahn M.-J; Wolf J; Seto T; Cho B.C; Patel M.R; Chiu C.-H; John T; Goto K; Karapetis C.S; Arkenau H.-T; Kim S.-W; Ohe Y; Li Y.-C; Chae Y.K; Chung C.H; Otterson G.A; Murakami H; Chia-Chi Lin; Tan D.S.W; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson T.R; Doebele R.C. |
| 臺大學術典藏 |
2020-05-25T07:35:02Z |
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-�] and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial
|
Paz-Ares L; Kim T.M; Vicente D; Felip E; Lee D.H; Lee K.H; Chia-Chi Lin; Flor M.J; Di Nicola M; Alvarez R.M; Dussault I; Helwig C; Ojalvo L.S; Gulley J.L; Cho B.C. |
| 臺大學術典藏 |
2020-04-28T07:25:09Z |
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
|
Kato K.; Cho B.C.; Takahashi M.; Okada M.; Lin C.-Y.; Chin K.; Kadowaki S.; Ahn M.-J.; Hamamoto Y.; Doki Y.; Yen C.-C.; Kubota Y.; Kim S.-B.; CHIH-HUNG HSU; Holtved E.; Xynos I.; Kodani M.; Kitagawa Y.; Kato K.;Cho B.C.;Takahashi M.;Okada M.;Lin C.-Y.;Chin K.;Kadowaki S.;Ahn M.-J.;Hamamoto Y.;Doki Y.;Yen C.-C.;Kubota Y.;Kim S.-B.;Chih-Hung Hsu;Holtved E.;Xynos I.;Kodani M.;Kitagawa Y. |
| 臺大學術典藏 |
2020-04-28T07:25:09Z |
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
|
Kato K.; Cho B.C.; Takahashi M.; Okada M.; Lin C.-Y.; Chin K.; Kadowaki S.; Ahn M.-J.; Hamamoto Y.; Doki Y.; Yen C.-C.; Kubota Y.; Kim S.-B.; CHIH-HUNG HSU; Holtved E.; Xynos I.; Kodani M.; Kitagawa Y.; Kato K.;Cho B.C.;Takahashi M.;Okada M.;Lin C.-Y.;Chin K.;Kadowaki S.;Ahn M.-J.;Hamamoto Y.;Doki Y.;Yen C.-C.;Kubota Y.;Kim S.-B.;Chih-Hung Hsu;Holtved E.;Xynos I.;Kodani M.;Kitagawa Y. |
| 國立成功大學 |
2020 |
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
|
Sequist, L.V.;Han, J.-Y.;Ahn, M.-J.;Cho, B.C.;Yu, H.;Kim, S.-W.;Yang, J.C.-H.;Lee, J.S.;Su, W.-C.;Kowalski, D.;Orlov, S.;Cantarini, M.;Verheijen, R.B.;Mellemgaard, A.;Ottesen, L.;Frewer, P.;Ou, X.;Oxnard, G. |
| 國立成功大學 |
2020 |
Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1‒positive, advanced non‒small-cell lung cancer in the KEYNOTE-010 study
|
Herbst, R.S.;Garon, E.B.;Dong-Wan, K.;Cho, B.C.;Perez-Gracia, J.L.;Ji-Youn, H.;Arvis, C.D.;Majem, Majem M.;Forster, M.D.;Monnet, I.;Novello, S.;Szalai, Z.;Gubens, M.A.;Wu-Chou, S.;Ceresoli, G.L.;Samkari, A.;Jensen, E.H.;Lubiniecki, G.M.;Baas, P. |
| 臺大學術典藏 |
2018 |
Updated results of M7824 (MSB0011359C): A bifunctional fusion protein targeting TGF-�] and PD-L1, in second-line (2L) NSCLC
|
Paz-Ares L; Kim T.M; Vicente D; Felip E; Lee D.H; Lee K.H; Chia-Chi Lin; Oncala M.J.F; Di Nicola M; Alvarez R.M; Dussault I; Helwig C; Ojalvo L; Gulley J; Cho B.C. |
| 臺大學術典藏 |
2017 |
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
|
Ahn M.-J; Kim D.-W; Cho B.C; Kim S.-W; Lee J.S; Ahn J.-S; Kim T.M; Lin C.-C; Kim H.R; John T; Kao S; Goldman J.W; Su W.-C; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; CHIH-HSIN YANG; Chih-Hsin Yang;Yang Z;Overend P;Harrop B;Rabbie S;Natale R;Su W.-C;Goldman J.W;Kao S;John T;Kim H.R;Lin C.-C;Kim T.M;Ahn J.-S;Lee J.S;Kim S.-W;Cho B.C;Kim D.-W;Ahn M.-J |
| 臺大學術典藏 |
2017 |
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
|
Ahn M.-J; Kim D.-W; Cho B.C; Kim S.-W; Lee J.S; Ahn J.-S; Kim T.M; Lin C.-C; Kim H.R; John T; Kao S; Goldman J.W; Su W.-C; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; CHIH-HSIN YANG; Chih-Hsin Yang;Yang Z;Overend P;Harrop B;Rabbie S;Natale R;Su W.-C;Goldman J.W;Kao S;John T;Kim H.R;Lin C.-C;Kim T.M;Ahn J.-S;Lee J.S;Kim S.-W;Cho B.C;Kim D.-W;Ahn M.-J |
| 國立成功大學 |
2017 |
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
|
Ahn, M.-J.;Kim, D.-W.;Cho, B.C.;Kim, S.-W.;Lee, J.S.;Ahn, J.-S.;Kim, T.M.;Lin, C.-C.;Kim, H.R.;John, T.;Kao, S.;Goldman, J.W.;Su, W.-C.;Natale, R.;Rabbie, S.;Harrop, B.;Overend, P.;Yang, Z.;Yang, J.C.-H. |
